Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius Stedim BiotechSRTOY +4.44%82 Cyclically Adjusted PB Ratio is 7.14 as of Jul. 23, 2026, which is 37% below its 10-year median of 11.27. GuruFocus rates SRTOY with a GF Score™ of 82/100 and a GF Value™ of $23.85 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 522 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks worse than 89.46% on this metric.
The historical rank and industry rank for Sartorius Stedim Biotech's Cyclically Adjusted PB Ratio or its related term are showing as below:
SRTOY'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 6.45 Med: 11.27 Max: 37.75
Current: 7.68
During the past years, Sartorius Stedim Biotech's highest Cyclically Adjusted PB Ratio was 37.75. The lowest was 6.45. And the median was 11.27.
SRTOY's Cyclically Adjusted PB Ratio is ranked worse than 89.46% of 522
companies
in the Medical Devices & Instruments industry
Industry Median: 1.765
vs SRTOY: 7.68
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Sartorius Stedim Biotech's adjusted book value per share data for the three months ended in Mar. 2026 was $4.882. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.80 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Sartorius Stedim Biotech (OTCPK:SRTOY) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Sartorius Stedim Biotech Cyclically Adjusted PB Ratio Related Terms
Sartorius Stedim Biotech Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Sartorius Stedim Biotech's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech Cyclically Adjusted PB Ratio Chart
SRTOY vs ISRG, BDX, MDLN: Cyclically Adjusted PB Ratio Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's Cyclically Adjusted PB Ratio falls into.
Sartorius Stedim Biotech Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 7.14 mean?
Sartorius Stedim Biotech (SRTOY) has a Cyclically Adjusted PB Ratio of 7.14 as of Jul. 23, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Sartorius Stedim Biotech and its competitors. This is 37% below median its historical median of 11.27. Over the past decade, Sartorius Stedim Biotech's Cyclically Adjusted PB Ratio has ranged from 6.45 to 37.75. According to the industry distribution chart, Sartorius Stedim Biotech ranks #467 out of 522 companies in the Medical Devices & Instruments industry, placing it in the top 89.5%.
Is Sartorius Stedim Biotech's Cyclically Adjusted PB Ratio too high?
Sartorius Stedim Biotech's current Cyclically Adjusted PB Ratio of 7.14 is 37% below median its 10-year median of 11.27. Over the past 10 years, this metric has ranged from a low of 6.45 to a high of 37.75. The Medical Devices & Instruments industry median Cyclically Adjusted PB Ratio is 1.77. Sartorius Stedim Biotech's value of 7.14 is 304.5% above this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #467 out of 522 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Cyclically Adjusted PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #467 out of 522 companies for Cyclically Adjusted PB Ratio. This places Sartorius Stedim Biotech in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.77. Sartorius Stedim Biotech's value of 7.14 is 304.5% above this benchmark. Historically, Sartorius Stedim Biotech's own Cyclically Adjusted PB Ratio has ranged from 6.45 to 37.75 over the past decade. While the company's 10-year median is 11.27 vs. the industry median of 1.77, Sartorius Stedim Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PB Ratio among Medical Devices & Instruments companies is 1.77, based on 522 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current Cyclically Adjusted PB Ratio of 7.14 is 304.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PB Ratio is 1.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current Cyclically Adjusted PB Ratio is 7.14, which is 37% below median its own 10-year median of 11.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (SRTOY) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.85, compared to a current price of $19.98 — trading 16.2% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 7.14, which is 37% below median its 10-year median of 11.27 and 304.5% above the Medical Devices & Instruments industry median of 1.77. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Sartorius Stedim Biotech (SRTOY), the current Cyclically Adjusted PB Ratio is 7.14 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (SRTOY) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of $19.98 is trading 16.2% below its estimated GF Value™ of $23.85.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for SRTOY:
Cyclically Adjusted PB Ratio: 7.14 (37% below median its 10-year median of 11.27)
GF Value™: $23.85 vs. price of $19.98 (16.2% below fair value)
Industry Position: 304.5% above the Medical Devices & Instruments median (#467 of 522)
No single metric tells the full story. See the SRTOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score
Get the complete analysis for SRTOY
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTOY has been successfully added to your 
